A recently published staffing model survey has brought new insights into oncology pharmacy operations across the country.

The Hematology/Oncology Pharmacy Association Practice Outcomes and Professional Benchmarking Committee (POPBC) Oncology Pharmacy Staffing Model Task Force developed a survey-based study in order to help provide an outline of oncology pharmacy staffing and operation practices. Distributed between September 2021 and January 2022, the survey collected baseline data and staffing metrics for oncology pharmacies - including facilities, inpatient and outpatient services, informatics/technology and more. The responses not only provided further insight into the unique oncology pharmacy operations and staffing models around the country, but also highlighted a need for staffing model benchmarking and metrics.

The full results are now published in the Journal of Oncology Pharmacy Practice.


Authors: Andrew Wechter, Anne M. McDonnell, Emily Zimdars, Leanne Sakamoto and Mark Hamm

Read the full article here

An image of multiple myeloma cells
HOPA News Late Breaking News

Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma

Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.

A doctor's hands holding an image of lungs
HOPA News Late Breaking News

Late-Breaking HOPA News: NeoADAURA: Advancing Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP, breaks down the results from the NeoADAURA trial and what its findings may mean for neoadjuvant osimertinib's role in the treatment of resectable EGFR-mutated NSCLC.

Cancer cells in a blood stream
HOPA News Late Breaking News

Late-Breaking HOPA News: Belantamab Mafodotin-bmlf Returns: FDA Restores BCMA-Targeted ADC Option for RRMM

Marshall Winget, PharmD, and Bradley Yelvington, PharmD, BCOP, discuss the recent reapproval of belantamab mafodotin in BCMA-directed therapy for relapsed or refractory multiple myeloma.